Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ClearPoint NeuroCLPT +1.61%63 Receivables Turnover is 1.28 as of Jun. 2026. GuruFocus rates CLPT with a GF Score™ of 63/100 and a GF Value™ of $14.14 (Fairly Valued). The stock has 8 warning signs investors should review. Among 813 Medical Devices & Instruments companies, ClearPoint Neuro ranks better than 62.98% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. ClearPoint Neuro's Revenue for the
three
months ended in Jun. 2026 was $10.88 Mil. ClearPoint Neuro's average Accounts Receivable for the
three
months ended in Jun. 2026 was $8.53 Mil.
Hence, ClearPoint Neuro's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.28.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
ClearPoint Neuro Receivables Turnover Related Terms
ClearPoint Neuro Receivables Turnover Historical Data
* Premium members only.
The historical data trend for ClearPoint Neuro's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLPT vs SI, PACB, DCTH: Receivables Turnover Comparison
For the Medical Devices subindustry, ClearPoint Neuro's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ClearPoint Neuro Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where ClearPoint Neuro's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ClearPoint Neuro (CLPT) has a Receivables Turnover of 1.28 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on ClearPoint Neuro and its competitors. According to the industry distribution chart, ClearPoint Neuro ranks #301 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 37%.
Is ClearPoint Neuro's Receivables Turnover too high?
ClearPoint Neuro's current Receivables Turnover is 1.28. The Medical Devices & Instruments industry median Receivables Turnover is 5.60. ClearPoint Neuro's value of 1.28 is 77.1% below this industry median. Based on the distribution chart, ClearPoint Neuro ranks #301 out of 813 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ClearPoint Neuro has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ClearPoint Neuro's Receivables Turnover compare to SI and PACB?
According to the Medical Devices & Instruments industry distribution chart, ClearPoint Neuro ranks #301 out of 813 companies for Receivables Turnover. This puts ClearPoint Neuro in the upper half of its industry. The industry median Receivables Turnover is 5.60. ClearPoint Neuro's value of 1.28 is 77.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.60, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ClearPoint Neuro's current Receivables Turnover of 1.28 is 77.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on ClearPoint Neuro and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ClearPoint Neuro's current Receivables Turnover is 1.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClearPoint Neuro stock overvalued right now?
Based on GuruFocus' analysis, ClearPoint Neuro (CLPT) is currently considered Fairly Valued. The stock's GF Value™ is $14.14, compared to a current price of $15.13 — trading 7% above its estimated fair value. The current Receivables Turnover is 1.28 and 77.1% below the Medical Devices & Instruments industry median of 5.60. ClearPoint Neuro's overall GF Score™ is 63/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For ClearPoint Neuro (CLPT), the current Receivables Turnover is 1.28 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ClearPoint Neuro (CLPT) Overvalued in 2026?
Based on GuruFocus' analysis, ClearPoint Neuro stock appears to be overvalued.
The current stock price of $15.13 is trading 7% above its estimated GF Value™ of $14.14.
GuruFocus considers ClearPoint Neuro to be Fairly Valued.
Key valuation signals for CLPT:
Receivables Turnover: 1.28
GF Value™: $14.14 vs. price of $15.13 (7% above fair value)
Industry Position: 77.1% below the Medical Devices & Instruments median (#301 of 813)
No single metric tells the full story. See the CLPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
63GF Score
Get the complete analysis for CLPT
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPT has been successfully added to your 
